Table 2 General characteristics of the participants
From: A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma
PCa and ADT (n= 26,082) | p* | PCa w/ADT (n= 51,605) | p** | Controls (n= 1,066) | p*** | |
|---|---|---|---|---|---|---|
Age (years) | 72.3 ± 3.12 | > 0.05 | 70.2 ± 2.81 | > 0.05 | 70.3 ± 3.30 | > 0.05 |
ADT time (months) | 36.9 ± 31.2 | --- | --- | --- | --- | --- |
Total BMD (g/cm2) | 0.90 ± 0.34 | 0.031 | 1.07 ± 0.11 | 0.760 | 0.96 ± 0.20 | 0.895 |
LS BMD (g/cm2) | 1.02 ± 0.10 | 0.083 | 1.10 ± 0.13 | 0.806 | 1.05 ± 0.18 | 0.868 |
TH BMD (g/cm2) | 0.89 ± 0.08 | 0.002 | 1.010.08 | 0.823 | 0.97 ± 0.03 | 0.211 |
t score (Total) | -1.30 ± 1.10 | 0.282 | -0.26 ± 1.14 | --- | --- | --- |
t score (LS) | -0.27 ± 1.21 | 0.031 | 0.25 ± 0.07 | --- | --- | --- |
t score (TH) | -0.94 ± 0.24 | 0.021 | -0.55 ± 0.07 | --- | --- | --- |
z score (Total) | -0.30 ± 0.69 | 0.164 | 0.54 ± 0.15 | --- | --- | --- |
z score (LS) | -0.27 ± 1.31 | --- | --- | --- | --- | --- |
z score (TH) | -0.33 ± 0,65 | 0.555 | 0.05 ± 0.35 | --- | --- | --- |
Osteoporosis (%) | 5.30 | < 0.001 | 2.89 | < 0.001 | 10.3 | < 0.001 |
Osteopenia (%) | 1.01 | < 0.001 | 0.15 | < 0.001 | 1.4 | 0.278 |
Fracture (%) | 17.56 | < 0.001 | 15.62 | < 0.001 | 1.5 | < 0.001 |
Vertebral fracture (%) | 2.96 | < 0.001 | 1.90 | --- | --- | --- |
Superior member fracture (%) | 4.45 | < 0.001 | 2.47 | --- | --- | --- |
Inferior member fracture (%) | 9.77 | < 0.001 | 7.38 | --- | --- | --- |